Roche Holding AG may get the first signs at a cardiology conference this month that the Swiss drugmaker can garner $6.8 billion in sales with a pill to combat heart disease by raising so-called good cholesterol.
GlaxoSmithKline Plc agreed to pay about $60 million in the first settlements of lawsuits alleging the company’s Avandia diabetes drug causes heart attacks and strokes in some users, people familiar with the accords said.
The California Public Employees Retirement System sued former Lehman Brothers Holdings Inc. executives and underwriters alleging they hid Lehman’s exposure to subprime loans when they sold the pension fund about $700 million in bonds.
AstraZeneca Plc named Martin Mackay to lead research and development, hiring a Pfizer Inc. executive for the second time this year as the U.K. drugmaker seeks to replace revenue it’s losing to generic competitors.
Novartis AG gained the most in four months in Zurich trading after first-quarter sales and profit surpassed analyst forecasts on higher revenue from a generic blood thinner and the Gleevec cancer medicine.
GlaxoSmithKline Plc agreed to pay $3 billion to resolve U.S. criminal and civil investigations into whether the U.K. company marketed drugs for unapproved uses and other matters, its biggest legal settlement.